Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 11, 2012, Pages 2022-2032

  Mackey, Rachel H ^a   Fanelli, Theresa J ^a   Modugno, Francesmary ^a,b   Cauley, Jane A ^a   McTigue, Kathleen M ^a,b   Brooks, Maria Mori ^a   Chlebowski, Rowan T ^c   Manson, JoAnn E ^d   Klug, Thomas L ^e   Kip, Kevin E ^e   Curb, J David ^f   Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f University of South Florida ^*

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTROGEN; ESTROGEN PLUS PROGESTIN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; ESTROGEN METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FEMALE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARIECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; RISK FACTORS; UNITED STATES;

EID: 84869233346     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0759     Document Type: Article

References (35)

1. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16. (Pubitemid 34498648)
2. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071-82. (Pubitemid 41815798)
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
4. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12. (Pubitemid 38489892)
6. Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O'Sullivan MJ, et al. The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women. Menopause 2010;17:622-9.
7. Farhat GN,Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011;103:562-70.
8. Okobia MN, Bunker CH. Estrogen metabolism and breast cancer risk - a review. Afr J Reprod Health 2006;10:13-25.
9. Sepkovic DW, Bradlow HL. Estrogen hydroxylation - the good and the bad. Ann N Y Acad Sci 2009;1155:57-67.
10. Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd-Morin J, et al. A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 2010;121:538-45.
11. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988;85:7831-5.
12. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79:3047-51. (Pubitemid 12058614)
13. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984;20:1077-81. (Pubitemid 14101045)
14. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A 1985;82:6295-9. (Pubitemid 16222871)
15. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992;84:634-8.
16. Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9. (Pubitemid 27295229)
17. Kabat GC, O'Leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, et al. Estrogen metabolism and breast cancer. Epidemiology 2006;17:80-8.
18. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
19. Fowke JH, Qi D, Bradlow HL, Shu XO, Gao YT, Cheng JR, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 2003;68:65-72. (Pubitemid 35418304)
20. Im A, Vogel VG, Ahrendt G, Lloyd S, Ragin C, Garte S, et al. Urinary estrogen metabolites in women at high risk for breast cancer. Carcinogenesis 2009;30:1532-5.
21. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5. (Pubitemid 28479160)
22. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, et al. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067-72. (Pubitemid 29293046)
23. Cauley JA, Zmuda JM, Danielson ME, Ljung BM, Bauer DC, Cummings SR, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003;14:740-4. (Pubitemid 40417025)
24. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005;14:2137-42. (Pubitemid 41603258)
25. Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18:2273-9.
26. Modugno F, Kip KE, Cochrane B, Kuller L, Klug TL, Rohan TE, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer 2006;118:1292-301. (Pubitemid 43185620)
27. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
28. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:S18-77. (Pubitemid 37324176)
29. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:S5-17.
30. Kuller LH, Matthews KA, Meilahn EN. Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis. J Steroid Biochem Mol Biol 2000;74:297-309. (Pubitemid 32126242)
31. Kuller LH, Pettee Gabriel KK, Kinzel LS, Underwood DA, Conroy MB, Chang Y, et al. The Women on the Move Through Activity and Nutrition (WOMAN) study: final 48-month results. Obesity (Silver Spring) 2012;20:636-43.
32. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
33. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012;104:326-39.
34. Bradlow HL, Jernstrom H, Sepkovic DW, Klug TL, Narod SA. Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites. Mol Genet Metab 2006;87:135-46. (Pubitemid 43199870)
35. Taioli E, Im A, Xu X, Veenstra TD, Ahrendt G, Garte S. Comparison of estrogens and estrogen metabolites in human breast tissue and urine. Reprod Biol Endocrinol 2010;8:93.